In vitro and in vivo studies on the anticancer activity of dehydroilludin M.

Abstract

Six first-generation illudin analogs were tested for antitumor activity using in vitro cytotoxicity and in vivo xenograft models. One analog, dehydroilludin M, inhibited xenograft growth and prolonged life span of tumor bearing animals, when administered IP or IV, whereas the parent Illudin S compound was ineffective. The efficacy of dehydroilludin M in the MV522 lung carcinoma model exceeded that of 9 known anticancer drugs, and equaled that of mitomycin C. Dehydroilludin M retained the in vitro relative selective cytotoxicity for carcinomas and myeloid leukemia cell lines noted with the parent illudin compounds. In vitro cytotoxicity data predicted response of xenografts. Dehydroilludin M also retained the in vitro activity of the parent compounds against different multidrug resistant mdr cell lines.

• Authors: M J Kelner, T C McMorris, R Taetle
• Journal: Anticancer research (Anticancer Res) 1995 May-Jun Vol. 15 Issue 3 Pg. 873-8 ISSN: 0250-7005 [Print] Greece
• PMID: 7645974 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Antineoplastic Agents
• Sesquiterpenes
• dehydroilludin M

Topics

• Analysis of Variance
• Animals
• Antibiotics, Antineoplastic (therapeutic use, toxicity)
• Antineoplastic Agents (therapeutic use, toxicity)
• Breast Neoplasms
• Cell Survival (drug effects)
• Colonic Neoplasms
• Humans
• Leukemia, Myeloid
• Leukemia, Promyelocytic, Acute (drug therapy)
• Lung Neoplasms
• Melanoma
• Mice
• Mice, Nude
• Molecular Structure
• Sesquiterpenes (isolation & purification, therapeutic use, toxicity)
• Structure-Activity Relationship
• Transplantation, Heterologous
• Tumor Cells, Cultured